Financial Performance - The total revenue for the third quarter was ¥289,137,508.42, representing a decrease of 26.53% compared to the previous quarter [20]. - The net profit attributable to shareholders of the listed company was ¥59,152,950.87, down 58.10% from the previous quarter [20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥54,410,014.11, a decrease of 60.05% compared to the previous quarter [20]. - The company reported a total profit of ¥334,621,662.96 for the period, down from ¥376,281,112.77 in the previous quarter [15]. - The company experienced a decrease in comprehensive income attributable to shareholders, totaling ¥285,890,455.63 for the quarter, compared to ¥321,964,378.52 in the previous quarter [15]. - The net profit for the period was CNY 334,765,260.53, down 11.03% from CNY 376,341,173.73 in the same quarter last year [32]. Research and Development - Total R&D expenses for the first nine months of 2023 reached ¥79,882,546.84, an increase of 33.97% compared to ¥59,627,214.97 in the same period of 2022 [7]. - Research and development expenses rose to CNY 79,882,546.84, an increase of 33.93% compared to CNY 59,627,214.97 in Q3 2022 [32]. - The company plans to expand its R&D office space, which contributed to a 68.46% increase in lease liabilities to ¥6,614,944.42 from ¥3,926,794.65 in the previous year [7]. Income and Expenses - Investment income surged to ¥12,855,969.32, a remarkable increase of 3230.34% from ¥386,025.67 in the previous year [7]. - Other income rose by 48.06% to ¥12,443,558.06, compared to ¥8,404,548.70 in the same period last year, attributed to increased government subsidies [7]. - The company received a total of ¥10,065.77 in non-operating income, which is a 141.77% increase from ¥4,163.42 in the previous year [7]. - The fair value change income was reported at ¥207,521.23, a 140.01% increase from a loss of -¥518,693.07 in the previous year [7]. - The company reported a 225.73% increase in construction in progress, reaching CNY 129,046,922.91, up from CNY 39,618,116.15 [23]. - The total non-operating income and expenses for the current period is ¥4,742,936.76, down from ¥21,501,262.81 in the previous period [47]. Taxation - The company reported a 54.57% decrease in taxes and surcharges, totaling ¥2,924,844.43, down from ¥6,438,740.19 in 2022 [7]. - The company’s tax expenses decreased by 30.07% to ¥34,550,284.25, down from ¥49,408,885.03 in the same period last year due to tax incentives for subsidiaries [7]. Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was ¥268,428,729.92, an increase of 34.10% year-over-year [20]. - The cash and cash equivalents at the end of the period were ¥1,124,089,840.87, reflecting a net increase of ¥65,136,709.56 during the quarter [17]. - The total cash inflow from investment activities is ¥2,579,644,558.12, significantly higher than ¥272,279,745.92 in the previous period [57]. - The net cash flow from investment activities is -¥61,140,353.45, an improvement from -¥136,974,428.80 in the previous period [57]. - The total cash outflow from investment activities is ¥2,640,784,911.57, compared to ¥409,254,174.72 in the previous period [57]. - The cash received from other operating activities is ¥51,424,439.05, an increase from ¥24,263,422.75 in the previous period [57]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,324, with the largest shareholder holding 45.74% [7]. - The equity attributable to shareholders of the listed company was ¥3,164,940,315.71, up 4.75% from the end of the previous year [20]. - The total equity attributable to shareholders increased to CNY 3,164,940,315.71, up from CNY 3,021,380,860.08, marking a growth of 4.75% [37]. - Basic earnings per share for the third quarter were ¥0.15, down 61.54% compared to the previous quarter [20]. Liabilities - The total liabilities decreased to CNY 317,879,912.64 from CNY 368,196,680.46, reflecting a reduction of 13.56% [37]. - Accounts receivable increased significantly by 661.00% to CNY 10,347,714.43 from CNY 1,359,759.60 [23]. - Other non-current assets surged by 727.94% to CNY 28,614,348.68, compared to CNY 3,456,081.12 in the previous period [23].

深圳市美好创亿医疗科技股份有限公司 关于公司部分首次公开发行前已发行股份及首次公开发行战略 配售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为深圳市美好创亿医疗科技股份有限公司（以下简 称"公司"）部分首次公开发行前已发行股份及首次公开发行战略配售股份。 2、本次申请解除股份限售的股东户数共计6户，解除限售股份的数量合计 71,899,458股，占公司总股本的比例为17.6805%，限售期为自公司首次公开发行 并上市之日起12个月。其中，首次公开发行前已发行的部分股份为67,890,000股， 占公司总股本的16.6945%，股东数量为5户；首次公开发行战略配售股份为 4,009,458股，占公司总股本的0.9859%，股东数量为1户。 证券代码：301363 证券简称：美好医疗 公告编号：2023-059 3、本次解除限售的股份上市流通日期为2023年10月12日（星期四）。 一、公司首次公开发行和股本变动情况 根据中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限 公司首次公开发行 ...

东兴证券股份有限公司（以下简称"东兴证券"或"保荐机构"）作为深圳 市美好创亿医疗科技股份有限公司（以下简称"美好医疗"、"上市公司"或"公 司"）首次公开发行股票并在创业板上市的保荐机构，根据《证券发行上市保荐 业务管理办法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等相关法律、法规和规 范性文件的规定，对美好医疗首次公开发行网下配售限售股上市流通事项进行了 核查，具体情况如下： 一、公司首次公开发行和股本变动情况 根据中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号）和深圳证券交 易所《关于深圳市美好创亿医疗科技股份有限公司人民币普通股股票在创业板上 市的通知》（深证上〔2022〕986 号），公司首次向社会公众公开发行人民币普通 股（A 股）4,427 万股，并于 2022 年 10 月 12 日在深圳证券交易所创业板上市交 易。首次公开发行股票前，公司总股本 36,239 万股；首次公开发行股票完成后， 公司总股本为 40,666 万股。 截至本核 ...

证券代码：301363 证券简称：美好医疗 深圳市美好创亿医疗科技股份有限公司 投资者关系活动记录表 编号：2023-004 | 投资者 | 特定对象调研 □分析师会议 | | --- | --- | | 关系活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 其他（电话会议） | | 活动参 | 详见附件清单 | | 与人员 | | | 时间 | 2023 年 8 月 30 日 15:00-16:00 | | 地点 | 公司会议室 | | 上市公 | 董事长、总经理 熊小川先生 | | 司接待 | 董事、副总经理 周道福先生 | | 人员 | 董事会秘书 谭景霞女士 | | | 财务总监 牟健先生 | | | 主要提问及答复情况 | | | 问题一：根据 2023 年半年报显示公司未来有几个比较重要的战略方 | | | 向，请公司介绍一下相关最新进展情况。 | | | 答复：尊敬的投资者：您好！ | | | 公司的战略方向近半年保持稳定。公司专注于医疗器械领域，为 | | | 全球医疗器械百强客户以及细分市场龙头企业提供 CDMO 和 CRO | | ...

Financial Performance - The company reported a revenue of 482.6 million yuan for the first half of 2023, reflecting a year-on-year increase of 4.76%[4] - The total operating revenue for the first half of 2023 was CNY 754,161,189.13, an increase of 11.93% compared to CNY 673,994,661.83 in the same period of 2022[62] - The net profit for the first half of 2023 was CNY 114,151,922.64, indicating a positive performance compared to previous periods[50] - The company's net profit for the first half of 2023 reached ¥240,918,427.84, an increase of 29.7% compared to ¥185,692,994.26 in the same period of 2022[68] - Total operating revenue for the first half of 2023 was ¥427,204,314.72, down 7.3% from ¥460,896,417.49 in the first half of 2022[69] - The total comprehensive income attributable to the parent company was ¥233,756,701.31, up from ¥182,635,957.90 in the previous year, marking a 28.0% increase[68] - The total operating profit for the first half of 2023 was ¥269,183,082.22, an increase of 21.7% from ¥221,161,301.57 in the same period last year[1] - The company reported a total sales revenue of CNY 471,188,923.78 for the first half of 2023, down from CNY 550,943,917.34 in the same period of 2022, indicating a decline of approximately 14.4%[186] Cash Flow and Liquidity - The net cash flow from operating activities was ¥168,838,366.56, down from ¥197,900,422.66 in the first half of 2022, indicating a decrease of 14.7%[75] - The total cash and cash equivalents at the end of the period amounted to ¥1,136,949,445.95, up from ¥630,907,715.16 at the beginning of the period, showing a significant increase in liquidity[77] - The company's total current assets increased to ¥2,439,967,095.86 from ¥2,424,975,740.92, indicating growth in short-term financial health[98] - The total cash balance of CNY 1,258,365,560.98 as of the end of the period, an increase from CNY 1,230,410,052.20 at the beginning of the period, representing a growth of approximately 2.3%[125] - The total cash and cash equivalents at the end of June 2023 amount to CNY 770,065,749.25, up from CNY 411,787,537.62 at the end of June 2022[189] Expenses and Costs - The total operating costs for the first half of 2023 amounted to CNY 500,326,088.56, up from CNY 452,895,293.09 in the first half of 2022, reflecting a growth of 10.47%[62] - Research and development expenses increased to ¥52,520,580.70, representing a 39.7% rise from ¥37,581,071.71 in the previous year[1] - The company reported a decrease in sales expenses to ¥14,477,905.08, compared to ¥8,962,702.68 in the same period last year, reflecting a 61.6% increase[1] - The company recorded a financial expense of -¥38,259,808.04, which is an increase in costs compared to -¥22,782,615.98 in the previous year[1] Shareholder and Equity Information - The top ten shareholders hold a combined 1.22% and 0.99% of shares, amounting to 4,960,000 yuan and 4,030,000 yuan respectively[3] - The total equity at the end of the reporting period was CNY 2,645,332,482.64, slightly down from CNY 2,657,632,667.18 in the previous period[62] - The company's total equity attributable to shareholders rose to ¥3,112,806,561.39 from ¥3,021,380,860.08, reflecting an increase of approximately 3%[104] - The company's retained earnings increased to ¥1,047,247,856.56 from ¥948,660,428.72, showing a growth of about 10.4%[104] Strategic Focus and Future Outlook - The company is focusing on expanding its market presence and developing new technologies to enhance its product offerings[4] - Future guidance indicates a projected growth rate of approximately 10% for the next fiscal year, driven by new product launches[4] - The company is actively pursuing strategic acquisitions to bolster its competitive position in the healthcare technology sector[4] - Future outlook includes potential market expansion and strategic acquisitions to drive growth[62] Governance and Compliance - There are no changes in the controlling shareholder or actual controller during the reporting period, ensuring stability in governance[4] - The company has implemented significant accounting policies to ensure accurate financial reporting and compliance[53] - The company has not reported any changes in accounting policies or prior period error corrections during this reporting period[197]

证券代码：301363 证券简称：美好医疗 公告编号：2023-053 深圳市美好创亿医疗科技股份有限公司 第二届监事会第五次会议决议公告 二、监事会会议审议情况 经全体与会监事认真审议、充分讨论，会议审议并通过了以下议案： （一）审议通过《关于 2023 年半年度报告全文及其摘要的议案》 经核查，监事会认为：董事会编制和审核公司《2023年半年度报告全文及其 摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日在巨潮资讯网（www.cninfo.com.cn）披露的相关公 告。 表决结果：同意 3 票；反对 0 票；弃权 0 票。 （二）审议通过《关于 2023 年半年度募集资金存放与使用情况的专项报告 的议案》 1 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届监事会 第五次会议通知于2023年8月18日以书面、电话等方式送达全体监事，并于2023 年8月28 ...

关于深圳市美好创亿医疗科技股份有限公司 2023 年半年度持续督导跟踪报告 东兴证券股份有限公司 | 保荐机构名称：东兴证券股份有限公司 | 被保荐公司简称：美好医疗（股票代码 301363） | | --- | --- | | 保荐代表人姓名：于洁泉 | 联系电话：010-66555013 | | 保荐代表人姓名：李靖宇 | 联系电话：010-66555013 | | 公司及股东承诺事项 | 是否履 | 未履行承诺的原因 | | --- | --- | --- | | | 行承诺 | 及解决措施 | | 1.公司股东关于所持股份的流通限制及自愿锁定股份、持 | 是 | 不适用 | | 股及减持意向的承诺 | | | | 2.公司及公司控股股东、实际控制人、董事（独立董事除 外）、高级管理人员关于上市后三年内稳定股价的承诺 | 是 | 不适用 | | 3.公司及公司控股股东、实际控制人、董事、监事、高级管 | | | | 理人员关于招股说明书无虚假记载、误导性陈述或者重大 | 是 | 不适用 | | 遗漏的承诺 | | | 2 | 公司及股东承诺事项 | 是否履 | 未履行承诺的原因 | | --- | -- ...

证券代码：301363 证券简称：美好医疗 公告编号：2023-052 深圳市美好创亿医疗科技股份有限公司 第二届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳市美好创亿医疗科技股份有限公司（以下简称"公司"）第二届董事会 第五次会议通知于2023年8月18日以书面、电话等方式送达全体董事，并于2023 年8月28日以现场结合通讯的方式在公司会议室召开。本次会议由董事长熊小川 先生主持，会议应到董事7人，实际参会董事7人，其中王建新先生以通讯方式出 席。经全体与会董事确认，本次会议的召集、召开以及审议程序符合《中华人民 共和国公司法》《公司章程》和《董事会议事规则》等有关规定，会议形成的决 议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于 2023 年半年度报告全文及其摘要的议案》 公司董事会认为：《2023年半年度报告》及《2023年半年度报告摘要》真实、 准确、完整地反映了公司2023年半年度的财务状况和经营成果，不存在虚假记载、 误导性陈述和重大遗漏。 具体内容详见公司于同日在巨潮资讯网 ...

2023年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：深圳市美好创亿医疗科技股份有限公司 单位：人民币万元 | 非经营性资金占用 | | 占用方与上市公 | 上市公司核算 | 2023年半年度期初 | 2023年半年度占用 | 2023年半年度占用 | 2023年半年度偿还 | 2023年半年度期末 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 资金占用方名称 | 司的关联关系 | 的会计科目 | 占用资金余额 | 累计发生金额 （不含利息） | 资金的利息 （如有） | 累计发生金额 | 占用资金余额 | 占用形成原因 | | | 控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 前控股股东、实际控制人及其附属企业 | | | | | | | | | | | | 小 计 | - | - | - | | | | | | | - | | 其他关联方及其附属企业 | | | ...

深圳市美好创亿医疗科技股份有限公司 关于2023年上半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和深 圳证券交易所印发的《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》（深证上〔2022〕14 号）等相关规定，深圳市美好创亿医疗 科技股份有限公司（以下简称"公司"或"本公司"）编制了《关于 2023 年半年 度募集资金存放与使用情况的专项报告》，现将公司 2023 年半年度募集资金存放 与使用情况说明如下： 一、 募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意深圳市美好创亿医疗科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2022〕1441 号），本公司由主承 销商东兴证券股份有限公司采用余额包销方式，向社会公众公开发行人民币普通 股（A 股）股票 4,427.00 万股，发行价为 ...